A Research Update from the National Institute on Drug Abuse —
March 2007
Methamphetamine abuse is a significant problem in the United States
- Approximately 10 million people 12 years and older
have abused methamphetamine in their lifetimes; in
2005, approximately 500,000 were current users
(NSDUH).
- Abuse has been especially noteworthy in certain areas
of the country with indicators suggesting particular
problems in Hawaii, the West Coast states, rural areas
of the West and, more recently, the Midwest.
- According to NIDA's 2006 Monitoring the Future Survey,
there has been a significant decline of past year
methamphetamine abuse by 10th graders; however,
during the same time period the abuse rate among 8th
and 12th graders did not change (Figure 1).
- Methamphetamine's potent addiction liability and
destructive health and social consequences make its abuse particularly dangerous.
Methamphetamine acts by increasing the release of dopamine in the brain, which leads to feelings of euphoria.
However, this influx of pleasure is followed by a "crash" that often leads to increased use of the drug and
eventually to difficulty feeling any pleasure at all, especially from natural rewards. Long-term methamphetamine
abuse also results in many damaging physical and psychiatric effects, such as:
- Addiction;
- Violent Behavior;
- Anxiety;
- Confusion;
- Insomnia;
- Psychotic features (e.g. paranoia, hallucinations, delusions); and
- Cardiovascular problems (e.g. rapid heart rate, irregular heartbeat, increased blood pressure, stroke).
What Does Methamphetamine Do to the Brain?
Methamphetamine's adverse effects on the brain are clear. In
animals, methamphetamine damages nerve terminals in brain
regions containing dopamine and serotonin, two chemicals
essential for normal functioning of the central nervous system.
Similarly, in humans, methamphetamine alters the brain in ways
that impair decision-making, memory, and motor behaviors, and
causes structural and functional deficits in brain areas associated
with depression and anxiety. Dopamine cell death, however, has
not been documented in methamphetamine abusers, which could
explain why extended abstinence allows for some recovery from
methamphetamine-induced deficits in dopamine function (Figure
2). But even though a recent neuroimaging study of
methamphetamine abusers showed partial recovery of brain function in some regions following protracted abstinence, function in other regions did not display recovery even
after two years of abstinence7ndash; suggesting that long-lasting and even permanent brain changes may result from
methamphetamine abuse.
Methamphetamine and HIV
In addition to its harmful effects on the brain, methamphetamine is inextricably linked with HIV, hepatitis C, and
other sexually transmitted diseases. Its abuse increases the risk of contracting HIV not only through the use of
contaminated injection equipment, but also through increased risky sexual behaviors and through physiological
changes that may favor HIV transmission.
Methamphetamine abuse may also affect HIV disease progression. For example, clinical studies suggest that
current methamphetamine abusers on highly active antiretroviral therapy may be at greater risk of developing
AIDS than non-users, possibly due to poor medication adherence or interactions between methamphetamine and
HIV medications. Similarly, preliminary studies suggest that interactions between methamphetamine and HIV itself
may lead to more severe consequences for HIV-positive patients who abuse methamphetamine, including greater
brain damage and cognitive impairment. More research is needed to better understand these interactions.
Treatments for Methamphetamine Addiction
Methamphetamine addiction can be successfully treated.
The Matrix Model, a proven effective treatment for
methamphetamine addiction, consists of a 16-week
intervention that includes intensive group and individual
therapy to promote the behavioral changes needed to
remain off drugs, prevent relapse, and establish a new
lifestyle unrelated to drugs. When applied to
methamphetamine abusers, the Matrix Model has been
shown to significantly reduce drug use (Figure 3).
Motivational Incentives for Enhancing Drug Abuse
Recovery (MIEDAR), an incentive-based method for
cocaine and methamphetamine abstinence, is another
treatment program that has recently demonstrated efficacy
in methamphetamine abusers through NIDA's National
Drug Abuse Clinical Trials Network.
NIDA is supporting the development of medications for all aspects of methamphetamine abuse and addiction. For
example, a recent clinical trial revealed that the antidepressant bupropion, marketed as Wellbutrin, ® is effective in
reducing methamphetamine abuse in low/moderate users. Because addiction changes the parts of the brain that
affect our ability to think, to control impulses, and to understand consequences, with methamphetamine in
particular exceeding other drugs in its disruption of cognition, and because drug-impaired cognitive functioning can
predict treatment dropout and lead to continued abuse and relapse, people undergoing methamphetamine
treatment also need medications to help them recover this functioning to give behavioral therapies the best chance
to work. A "rising star" in this arena is modafinil, a medication used to treat narcolepsy, which appears to improve
cognitive functioning, and may also complement behavioral counseling for methamphetamine abuse. To treat
methamphetamine overdose, NIDA is also developing antibodies to methamphetamine that will bind the drug in
the bloodstream and prevent its deleterious effects.